Novartis Seeks To Nix Expert Testimony In Bone Drug MDL

Law360, New York (May 20, 2011, 3:30 PM EDT) -- Novartis Pharmaceuticals Corp. asked a Tennessee federal judge on Thursday to exclude six experts' testimony in 30 suits in a multidistrict litigation over the bone cancer drugs Aredia and Zometa, the same day it sought to dismiss four of those cases.

The lawsuits in the MDL, which was consolidated in April 2006 and has involved hundreds of suits, accuse Novartis of failing to warn patients that its drugs Aredia and Zometa could cause osteonecrosis of the jaw, a condition involving the deterioration of the jawbone....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Aredia and Zometa Products Liability Litigation


Case Number

3:06-md-01760

Court

Tennessee Middle

Nature of Suit

Personal Inj. Prod. Liability

Judge

Todd J. Campbell

Date Filed

April 19, 2006

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.